MiNK Therapeutics, Inc., a biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies, announced the publication of a peer-reviewed article in Frontiers in ...
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) ...
Zacks Investment Research on MSN
Here's why you should add INKT stock to your portfolio now
MiNK Therapeutics INKT is focused on developing off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies for ...
Off-the-shelf and mass-producible immune cells fight solid human tumors engrafted into mice. The Kobe University development is a significant contribution towards faster and cheaper cancer ...
Trial is Supported by Stand Up To Cancer as Part of an Initiative to Find Treatments for the ~70% of Gastroesophageal Cancer (GEC) Patients for Whom Current Treatments Don't Work Randomized Phase 2 ...
MiNK Therapeutics Inc. INKT shares are up on Tuesday as the company has announced a strategic collaboration with C-Further to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric ...
Immunotherapy has transformed cancer treatment by harnessing the body's own immune system to fight disease. But many engineered immune cells lose strength quickly after they enter the body, especially ...
Off-the-shelf and mass-producible immune cells fight solid human tumors engrafted in mice. The Kobe University development is ...
Few cancer treatments are as ferocious as CAR T cell therapy. Often derived from a patient’s own immune cells, CAR T cells are genetically modified to hunt down and destroy cancer cells. The FDA has ...
MiNK Therapeutics, Inc. (NASDAQ:INKT) stock is trading higher on Friday, with a session volume of 20.2 million compared to the average volume of 7.5 million as per data from Benzinga Pro. The clinical ...
Immunotherapy has transformed cancer treatment by harnessing the body's own immune system to fight disease. But many engineered immune cells lose strength quickly after they enter the body, especially ...
Good morning, and welcome to MiNK Therapeutics' Second Quarter 2025 Conference Call and Webcast. [Operator Instructions] Please note that this event is being recorded. If anyone has any objections, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results